Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25963877 | 1.00 | MAOA (0.60) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL3086365 | 1.00 | MAOA (0.60) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL25963905 | 1.00 | MAOA (0.60) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL6528214 | 0.98 | MAOA (0.58) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL26840517 | 0.95 | TDP1 (0.67) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL13592519 | 0.95 | TDP1 (0.67) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL26840523 | 0.95 | TDP1 (0.67) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL14103937 | 0.95 | TDP1 (0.67) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL28051430 | 0.95 | TDP1 (0.67) | MAOAMAOBTDP1EPHX1CA12 | |
| SCHEMBL24140974 | 0.93 | MAOA (0.65) | MAOAMAOBTDP1EPHX1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140527-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140527-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | MAOA 2675/4885MAOB 3136/4885TDP1 4701/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | MAOA 2675/4885MAOB 3136/4885TDP1 4701/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | MAOA 2675/4885MAOB 3136/4885TDP1 4701/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | MAOA 2675/4885MAOB 3136/4885TDP1 4701/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | MAOA 2675/4885MAOB 3136/4885TDP1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.